title: [Pulmonary tuberculosis associated to adalimumab: a study of 3 cases].
abstract: Tumour necrosis factor-alpha antagonist drugs represent a significant advance in the treatment of inflammatory diseases, such as rheumatoid arthritis, spondyloarthropathies, and intestinal inflammatory disease. The increase in tuberculosis with infliximab is known, but there is less data available that specifically associates tuberculosis with adalimumab. We present the cases of 2 patients with rheumatoid arthritis and one patient with ankylopoietic spondylitis on treatment with adalimumab, who developed pulmonary and disseminated tuberculosis despite following the screening and prophylaxis measures recommended in guidelines. We also review the association between treatment with tumour necrosis factor-alpha antagonists and tuberculosis.
authors.affiliation: Servicio de Neumoloxía, Hospital Meixoeiro, Complexo Hospitalario Universitario de Vigo, Vigo, Pontevedra, Spain.
authors.forename: José J
authors.initials: JJ
authors.lastname: Blanco Pérez
authors.forename: Angel
authors.initials: A
authors.lastname: Aranda Torres
authors.forename: José M
authors.initials: JM
authors.lastname: Pego Reigosa
authors.forename: Manuel
authors.initials: M
authors.lastname: Núñez Delgado
authors.forename: Enrique
authors.initials: E
authors.lastname: Temes Montes
authors.forename: José Luis
authors.initials: JL
authors.lastname: Guerra Vales
mesh_terms: D000068879:Adalimumab; D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000627:therapeutic use; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000995:Antitubercular Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy; D004198:Disease Susceptibility; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D009894:Opportunistic Infections / Q000188:drug therapy / Q000209:etiology*; D013167:Spondylitis, Ankylosing / Q000150:complications / Q000188:drug therapy; D014391:Tuberculosis, Miliary / Q000188:drug therapy / Q000209:etiology; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy / Q000209:etiology*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000995:Antitubercular Agents; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab; D008727:Methotrexate